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numerous and have been generally inferred from the pedigree,
giving rise to the dominant and recessive incidence values (Fine
et al, 1999).
The new mutation rate for any of the forms of EB has not been
calculated; however, a number of sporadic cases of DEB have been
analyzed for mutations in the COL7A1 gene and are presumed to
result from germline mosaicism (Rouan et al, 1998; Hashimoto et al,
1999; Lee et al 2000). Continued elucidation of the mutations
involved in all forms of EB will allow us to further understand the
relative numbers of new mutations, and to correlate type of
mutation and pattern of inheritance.
The carrier incidence information provided in Table I should
enable genetics professionals to accurately calculate the risk of
recurrence to individual family members based on the family
history and provide up-to-date risk estimates that will facilitate
accurate counselling of extended families at risk.
Supported by grants from NIAMS/NIH (PO1 AR38923) of the United States
Public Health Service, and from the Dystrophic Epidermolysis Bullosa Research
Association of America (DebRA).
Ellen Pfendner, Jouni Uitto, Jo-David Fine*
Department of Dermatology and Cutaneous Biology and the
DebRA Molecular Diagnostics Laboratory, Thomas Jefferson
University, Philadelphia, Pennsylvania, U.S.A.
*Department of Dermatology and National Epidermolysis
Registry, University of North Carolina at Chapel Hill, Chapel Hill,
North Carolina, U.S.A.
REFERENCES
Chan Y, Anton-Lamprecht I, Yu QC, et al: A human keratin 14 ``knockout'': the
absence of K14 leads to severe epidermolysis bullosa simplex and a function for
an intermediate ®lament protein. Genes Dev 8:2574±2587, 1994
Christiano A, McGrath J, Uitto J: In¯uence of the second COL7A1 mutation in
determining the phenotypic severity of recessive dystrophic epidermolysis
bullosa. J Invest Dermatol 106:766±770, 1996
Fine J-D, Bauer EA, McGuire J, Moshell A (eds): Epidermolysis Bullosa: Clinical,
Epidemiologic and Laboratory Advances and the Findings of the National Epidermolysis
Bullosa Registry. Baltimore: The Johns Hopkins University Press, 1999
Fine J-D, Eady RAJ, Bauer EA, et al: Revised classi®cation system for inherited
epidermolysis bullosa: Report of the Second International Consensus Meeting
on diagnosis and classi®cation of epidermolysis bullosa. J Am Acad Dermatol
42:1051±1066, 2000
Gardella R, Belletti L, Zoppi N, et al: Identi®cation of two splicing mutations in the
collagen type VII gene (COL7A1) of a patient affected by the localisata variant
of recessive dystrophic epidermolysis bullosa. Am J Hum Genet 59:292±300,
1996
Hashimoto I, Kon A, Tamai K, Uitto J: Diagnostic dilemma of ``sporadic'' cases of
dystrophic epidermolysis bullosa: a new dominant or mitis recessive mutation?
Exp Dermatol 8:140±142, 1999
JaÈrvikallio A, Pulkkinen L, Uitto J: Molecular basis of dystrophic epidermolysis
bullosa: mutations in the type VII collagen gene (COL7A1). Hum Mut
10:338±347, 1997
Jonkman MF, Heeres K, Pas HH, et al: Effects of keratin 14 ablation on the clinical
and cellular phenotype in a kindred with recessive epidermolysis bullosa
simplex. J Invest Dermatol 5:764±769, 1996
Lee JY-Y, Li C, Chao S-C, Pulkkinen L, Uitto JA: De novo glycine substitution
mutation in the collagenous domain of COL7A1 in dominant dystrophic
epidermolysis bullosa. Arch Dermatol Res 292:159±163, 2000
Pulkkinen L, Uitto J: Mutation analysis and molecular genetics of epidermolysis
bullosa. Matrix Biol 18:29±42, 1999
Rouan F, Pulkkinen L, Jonkman M, et al: Novel and de novo glycine substitution
mutations in the type VII collagen gene (COL7A1) in dystrophic epidermolysis
bullosa: implications for genetic counseling. J Invest Dermatol 111:1210±1213,
1998
Rugg EL, McLean WHI, Lane EB, et al: A functional ``knockout'' of human keratin
14. Genes Dev 8:2563±2573, 1994
Tamai K, Murai T, Mayama M, et al: Recurrent COL7A1 mutations in Japanese
patients with dystrophic epidermolysis bullosa: positional effects of premature
termination codon mutations on clinical severity. J Invest Dermatol
112:991±993, 1999
A Peripheral Blood T Cell Clone is a Prognostic Marker in
Mycosis Fungoides
To the Editor:
Dr Muche and colleagues (2000) have raised several criticisms of
our recent article (Fraser-Andrews et al, 2000). Speci®cally they
question our ®ndings that a peripheral blood T cell clone is an
independent prognostic feature in mycosis fungoides (p = 0.03 with
a hazards ratio of 2.6 after adjusting for age, skin stage, and lymph
node stage). Our results are based on multivariate analysis of 66
patients with up to 10 y follow-up and crucially includes analysis of
data at diagnosis for the majority of patients. Whilst we acknow-
ledge that further prospective studies of larger numbers with longer
follow-up are required, their comment that ``the survival or time to
progression in stage of the reported mycosis fungoides (MF)
patients with or without periphreal blood T cell clonality'' is not
relevant if data are analyzed from diagnosis. In other words the
results at diagnosis give a measure of tumor burden that can then be
entered into a multivariate analysis. The reason for the authors
differing conclusions is because their study is not based on data at
the time of diagnosis and predominanlty consists of patients with
T1 and T2 MF and only four patients with T3 stage disease. In
addition the follow-up in their study is much shorter than ours.
They state that the presence of a peripheral blood T-cell clone
¯uctuated during the course of the disease in some of their patients,
which would be expected and might re¯ect a partial response to
different therapies. Once again this emphasises the importance of
analysing data from diagnosis. Inevitably they cannot perform a
multivariate analysis on these results and therefore cannot make any
conclusoins regarding the prognostic implications.
We agree that the proportion of peripheral blood T cell clones
detected will re¯ect the sensitivity of the method and certainly the
use of oligonucleotides for the tumor speci®c V(D)J clonal TCR
gene rearrangement would be too sensitive. Intriguingly the
relative proporitons of their T1/T2 patients with preipheral blood
T cell clones are similar to our ®ndings in early stage disease. This
suggests that the sensitivity of the two techniques are broadly
similar, which would be expected given that both methods depend
on distinguishing clonal rearrangements on the basis of sequence
and size. In fact our method employed monoplex rather than
multiplex polymerase chain reaction and radioactively labelled
products which should increase the sensitivity. There is certainly no
basis for the authors contention that our approach is less sensitive
but comparative studies would be worthwhile.
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The study by Laetsch et al has reveaeled similar ®ndings to our
study, namely that almost 75% of CTCL patients with stage III±IVb
disease have peripheral blood T cell clones. The essential aspect of
this study is that both the presence of a peripheral blood T cell
clone and the CD4+/CD7-cell count are independently correlated
with stage. They have not drawn any conclusions regarding the
prognostic signi®cance of their data as suggested by Muche et al.
Finally Muche et al speculate about physiologic recirculation of
tumor cells. We agree that tumor cells will recirculate physio-
logically but the detection of these cells can still represent a measure
of tumor burden and these two concepts are not mutually
exclusive.
E. Fraser Andrews, A. Woolford, R. Russell Jones, S. Whittaker
Skin Tumor Unit, St John's Institute of Dermatology,
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